oxybutynin
FDA Approved, EMA Approved
Description
Oxybutynin is an anticholinergic medication used to treat urinary symptoms including those associated with congenital urinary tract malformations. It reduces bladder muscle spasms and is commonly prescribed for neurogenic bladder and urinary incontinence. The medication is available in multiple formulations for flexible dosing.
Indications & Therapeutic Use
Neurogenic bladder, urinary incontinence, overactive bladder, congenital urinary tract disorders
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
oxybutynin
| Generic Name | oxybutynin |
| Brands | 1 brand available |
| Active Ingredient | oxybutynin chloride |
| Drug Class | Neurogenic bladder |
| Manufacturer | Janssen Pharmaceuticals |
| Dosage Forms | Oral tablet 5mg, extended-release tablet 5mg/10mg/15mg, transdermal patch 3.9mg/day |
| Medical Code | G04BD04 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00001234 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes